Intercept Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $11.26
- Today's High:
- $12.09
- Open Price:
- $11.26
- 52W Low:
- $8.82
- 52W High:
- $21.86
- Prev. Close:
- $11.45
- Volume:
- 830219
Company Statistics
- Market Cap.:
- $478.41 million
- Book Value:
- 1.617
- Revenue TTM:
- $306.48 million
- Operating Margin TTM:
- -21.82%
- Gross Profit TTM:
- $284.73 million
- Profit Margin:
- 68.07%
- Return on Assets TTM:
- -8.5%
- Return on Equity TTM:
- 0%
Company Profile
Intercept Pharmaceuticals Inc had its IPO on 2012-10-11 under the ticker symbol ICPT.
The company operates in the Healthcare sector and Biotechnology industry. Intercept Pharmaceuticals Inc has a staff strength of 341 employees.
Stock update
Shares of Intercept Pharmaceuticals Inc opened at $11.26 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $11.26 - $12.09, and closed at $11.86.
This is a +3.58% increase from the previous day's closing price.
A total volume of 830,219 shares were traded at the close of the day’s session.
In the last one week, shares of Intercept Pharmaceuticals Inc have increased by +5.33%.
Intercept Pharmaceuticals Inc's Key Ratios
Intercept Pharmaceuticals Inc has a market cap of $478.41 million, indicating a price to book ratio of 44.1919 and a price to sales ratio of 1.5996.
In the last 12-months Intercept Pharmaceuticals Inc’s revenue was $306.48 million with a gross profit of $284.73 million and an EBITDA of $-66520000. The EBITDA ratio measures Intercept Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Intercept Pharmaceuticals Inc’s operating margin was -21.82% while its return on assets stood at -8.5% with a return of equity of 0%.
In Q2, Intercept Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 16.7%.
Intercept Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 7.9872
- Trailing PE
- 0
- PEG
- -0.69
Its diluted EPS in the last 12-months stands at $-4.35 per share while it has a forward price to earnings multiple of 7.9872 and a PEG multiple of -0.69. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Intercept Pharmaceuticals Inc’s profitability.
Intercept Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.1855 and a EV to EBITDA ratio of -3.5929. Its price to sales ratio in the trailing 12-months stood at 1.5996.
Intercept Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $484.64 million
- Total Liabilities
- $187.02 million
- Operating Cash Flow
- $96.95 million
- Capital Expenditure
- $98000
- Dividend Payout Ratio
- 0%
Intercept Pharmaceuticals Inc ended 2024 with $484.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $484.64 million while shareholder equity stood at $67.55 million.
Intercept Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $187.02 million in other current liabilities, 42000.00 in common stock, $-2174885000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $136.23 million and cash and short-term investments were $414.99 million. The company’s total short-term debt was $109,808,000 while long-term debt stood at $223.60 million.
Intercept Pharmaceuticals Inc’s total current assets stands at $470.77 million while long-term investments were $0 and short-term investments were $277.63 million. Its net receivables were $29.79 million compared to accounts payable of $85000.00 and inventory worth $6.27 million.
In 2024, Intercept Pharmaceuticals Inc's operating cash flow was $96.95 million while its capital expenditure stood at $98000.
Comparatively, Intercept Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $11.86
- 52-Week High
- $21.86
- 52-Week Low
- $8.82
- Analyst Target Price
- $15.25
Intercept Pharmaceuticals Inc stock is currently trading at $11.86 per share. It touched a 52-week high of $21.86 and a 52-week low of $21.86. Analysts tracking the stock have a 12-month average target price of $15.25.
Its 50-day moving average was $10.77 and 200-day moving average was $14.17 The short ratio stood at 13.09 indicating a short percent outstanding of 0%.
Around 312.5% of the company’s stock are held by insiders while 8130.4% are held by institutions.
Frequently Asked Questions About Intercept Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.